emsam (deprenyl patch): how a promising antidepressant was underutilized [corrigendum]

emsam (deprenyl patch): how a promising antidepressant was underutilized [corrigendum]

;Asnis GM;Henderson MA
journal of crystal growth 2014 Vol. 2014 pp. 2069-2070
55
gm2014neuropsychiatricemsam

Abstract

Asnis GM, Henderson MA. Neuropsychiatr Dis Treat. 2014;10:1911–1923.On page 1921 “[…] Dye and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb” should be “Dey and now Mylan Pharmaceutical took over the marketing of EMSAM from Bristol-Myers Squibb”.On page 1921 “Both Dye and Mylan’s recent attempts at reanalysis […]” should be “Both Dey and Mylan’s recent attempts at reanalysis […]”.On page 1921 “With over 14 years left in the patent of EMSAM, [...]” should be “with 4 years left in the patent of EMSAM, [...]”. The authors apologize for these errors.Read the original article

Citation

ID: 210583
Ref Key: gm2014neuropsychiatricemsam
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
210583
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet